ZURICH (Reuters) – Novartis ag said its Kymriah to treat aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment did not meet its primary endpoint of event-free survival in a phase III study.
The safety profile was consistent with the established safety profile of Kymriah and Novartis will complete a full evaluation of the BELINDA study data, the Swiss drugmaker said in a statement on Tuesday.
(Reporting by Silke Koltrowitz; Editing by Riham Alkousaa)
